Hepatitis B Reactivation Following Eradication of HCV with Direct-Acting Antiviral Drugs (DAAs) in a Cohort of Patients from Different Institutions in Egypt.
J Clin Exp Hepatol
; 12(5): 1276-1284, 2022.
Article
em En
| MEDLINE
| ID: mdl-36157140
ALT, Alanine Aminotransferase; APASL, Asian Pacific Association for the Study of the Liver; APRI, Aspartate-aminotransferase-to-platelet-ratio index; ARFI, Acoustic Radiation Forced Impulse; AST, Aspartate Aminotransferase; CUC-HF, Cairo University Center for Hepatic Fibrosis; DAA, Direct-acting antivirals; DAAs; DNA, Deoxyribonucleic acid; EASL, European Association for the Study of the Liver; FIB-4, Fibrosis-4; HBV reactivation; HBV, Hepatitis B virus; HBV-DNA; HBVr, Hepatitis B virus reactivation; HBcAb, Hepatitis B core antibody total; HBsAg, Hepatitis B surface antigen; HCV; HCV, Hepatitis C virus; LSM, Liver stiffness measurement; MOHP, Ministry of Health and Population; PCR, Polymerase chain reaction; PegINF, Pegylated Interferon; ULN, upper limit of normal
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Tipo de estudo:
Risk_factors_studies
Idioma:
En
Revista:
J Clin Exp Hepatol
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
Egito